Search

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches

Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD

OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)

Alberta

Learn about Boehringer Ingelheim Canada's strategic partnerships with leading institutions in Alberta to advance quality healthcare.

Ontario

Boehringer Ingelheim Canada collaborates with premier institutions in Ontario to drive innovative solutions for high-quality healthcare. Click to read more.

Western Canada

Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.

Quebec

Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.

Purchasing

Purchasing at Boehringer Ingelheim

Corporate profile

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study

Boehringer Ingelheim - Value Through Innovation

boehringer-ingelheim-animal-health-bu-factsheet

Business Ethics

The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.

World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program

Laura loves her diverse career

Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

Application Platform Data privacy statement

(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Vision & values

Boehringer Ingelheim employees across the U.S. are out in their communities making a difference to help improve the lives of those who have been impacted by the coronavirus.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers